Reference number : GC-2017-Q4-00566, amendment number : , agreement type : G, recipient legal name : Fedida, David (The University of British Columbia), recipient country : CA, recipient province : nan, recipient city : British Columbia|Colombie-Britannique, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : During human clinical trials, a large percentage of candidate drugs fail because they are unsafe or ineffective._x000D_
Even when pre-clinical cell and animal studies seem positive, problems occur because tests done with drugs on_x000D_
these models are often not predictive of what happens in humans. Much of this is due to significant differences_x000D_
in biology between species._x000D_
For instance, ion channels (membrane proteins through which heart cells conduct electrical currents) can vary_x000D_
between humans and animals. Many drugs, including non-cardiovascular drugs, target these ion channels in the_x000D_
heart, which can potentially result in lethal arrhythmias. Thus, it is critical to use preclinical models that can_x000D_
closely reproduce what happens in humans to better predict drug safety._x000D_
To streamline the therapeutic development pipeline, we will develop a novel 3D bioprinted human cardiac_x000D_
tissue model which will improve the translational science process for predicting whether drugs will be safe and_x000D_
effective in humans. The goal is to develop 3D human cardiac tissue structure(s) that closely model the_x000D_
electrophysiological properties of the human heart, relevant to impulse conduction and arrhythmia generation._x000D_
We will use a known cardiac cell line, HL-1, that mimics human cardiac cells and and novel microfluidic based_x000D_
3D bioprinting technology and methodologies to build the 3D cardiac tissue. Ultimately, these models are_x000D_
expected to replace the use of animals to screen drugs for safety and efficacy._x000D_
To validate our models, we will evaluate the cardiotoxicity potential of a range of known compounds, and_x000D_
compare the outcome with data obtained using current standard assays. It takes on average over $2.5 billion to_x000D_
develop and gain marketing approval for a new drug. About $100 million is required to complete the_x000D_
pre-clinical studies alone. Using novel bioprinted models of cardiac tissue is expected to significantly cut the_x000D_
cost and time of bringing a new drug to market., program purpose french : During human clinical trials, a large percentage of candidate drugs fail because they are unsafe or ineffective._x000D_
Even when pre-clinical cell and animal studies seem positive, problems occur because tests done with drugs on_x000D_
these models are often not predictive of what happens in humans. Much of this is due to significant differences_x000D_
in biology between species._x000D_
For instance, ion channels (membrane proteins through which heart cells conduct electrical currents) can vary_x000D_
between humans and animals. Many drugs, including non-cardiovascular drugs, target these ion channels in the_x000D_
heart, which can potentially result in lethal arrhythmias. Thus, it is critical to use preclinical models that can_x000D_
closely reproduce what happens in humans to better predict drug safety._x000D_
To streamline the therapeutic development pipeline, we will develop a novel 3D bioprinted human cardiac_x000D_
tissue model which will improve the translational science process for predicting whether drugs will be safe and_x000D_
effective in humans. The goal is to develop 3D human cardiac tissue structure(s) that closely model the_x000D_
electrophysiological properties of the human heart, relevant to impulse conduction and arrhythmia generation._x000D_
We will use a known cardiac cell line, HL-1, that mimics human cardiac cells and and novel microfluidic based_x000D_
3D bioprinting technology and methodologies to build the 3D cardiac tissue. Ultimately, these models are_x000D_
expected to replace the use of animals to screen drugs for safety and efficacy._x000D_
To validate our models, we will evaluate the cardiotoxicity potential of a range of known compounds, and_x000D_
compare the outcome with data obtained using current standard assays. It takes on average over $2.5 billion to_x000D_
develop and gain marketing approval for a new drug. About $100 million is required to complete the_x000D_
pre-clinical studies alone. Using novel bioprinted models of cardiac tissue is expected to significantly cut the_x000D_
cost and time of bringing a new drug to market., agreement title english : 3D bioprinted cardiac tissue models, agreement title french : 3D bioprinted cardiac tissue models, agreement number : EGP, agreement value : 23000.0, agreement start date : 2018-03-07, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada